Surgeons Knowledge, Attitude, and Practice Toward Preoperative Inflammatory Bowel Disease Medications and Post-Operative Complications
Therapeutics and Clinical Risk Management · 2025-07 · Volume 21 · 1149-1159
DOI: 10.2147/tcrm.s527037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutics and Clinical Risk Management, 2025-07. Verfasst von Noura Alhassan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Research Chair, Department of Surgery, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Biologics, particularly anti-TNF agents, have transformed the management of inflammatory bowel disease (IBD), but concerns about their perioperative safety persist.
Objective
This study evaluates the knowledge, attitudes, and practices of surgeons in Saudi Arabia regarding the preoperative management of IBD patients undergoing surgery while on biological treatments.
Methods
A cross-sectional survey was conducted among 115 surgeons. Participants included general and colorectal surgeons with extensive experience in IBD management. Data were analyzed to assess knowledge, attitudes, and practices related to the impact of biologics, corticosteroids, and immunomodulators on wound healing and postoperative complications.
Results
The response rate of 67.8% and Most surgeons (74.4%) believed biologics negatively affect wound healing, despite evidence suggesting their safety. Corticosteroids were unanimously recognized for their adverse effects, while immunomodulators were widely perceived as safe. A majority preferred tapering biologics and corticosteroids 4 weeks preoperatively but continued immunomodulators. Differences between specialties were observed, with colorectal surgeons demonstrating greater adherence to evidence-based guidelines compared to general surgeons, who expressed more concerns about biologics' risks.
Conclusion
This study identifies a persistent gap between evidence and practice in the perioperative management of IBD patients on biologics among Saudi surgeons, with general surgeons often stopping biologics due to safety concerns despite evidence of their safety, while colorectal surgeons are more likely to follow current guidelines. Unnecessary cessation may increase disease flare risk, highlighting the need for targeted education and multidisciplinary collaboration to optimize surgical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Colorectal Research Chair, Department of Surgery, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
- Colorectal Surgery, Department of Surgery, King Fahad Specialist Hospital, Buraydah, Saudi Arabia.
- College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- Pharmacy Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
ORCID-Profile: Mohammed Basem Beyari, Saleh Husam Aldeligan
Zitieren
APA
Alhassan, N., Alnwdel, A. N., Beyari, M. B., Aldeligan, S. H., Alhassan, R., Abdulla, M. H., & Bin Traiki, T. (2025). Surgeons Knowledge, Attitude, and Practice Toward Preoperative Inflammatory Bowel Disease Medications and Post-Operative Complications. Therapeutics and Clinical Risk Management, Volume 21, 1149-1159. https://doi.org/10.2147/tcrm.s527037
Vancouver
Alhassan N, Alnwdel AN, Beyari MB, Aldeligan SH, Alhassan R, Abdulla MH, et al. Surgeons Knowledge, Attitude, and Practice Toward Preoperative Inflammatory Bowel Disease Medications and Post-Operative Complications. Therapeutics and Clinical Risk Management. 2025;Volume 21:1149-1159. doi:10.2147/tcrm.s527037
BibTeX
@article{Alhassan2025,
author = {Alhassan, Noura and Alnwdel, Abdullah Nasser and Beyari, Mohammed Basem and Aldeligan, Saleh Husam and Alhassan, Reem and Abdulla, Maha Hamadien and Bin Traiki, Thamer},
title = {Surgeons Knowledge, Attitude, and Practice Toward Preoperative Inflammatory Bowel Disease Medications and Post-Operative Complications},
journal = {Therapeutics and Clinical Risk Management},
year = {2025},
volume = {Volume 21},
pages = {1149--1159},
doi = {10.2147/tcrm.s527037}
}
EUVIMED